Ciclofosfamida oral metronómica en combinación con prednisona tras la progresión a docetaxel en pacientes afectados de un cáncer de próstata metastásico resistente a la castración (CPRC)

Estudi retrospectiu que avalua eficàcia i tolerabilitat de ciclofosfamida oral metronòmica (COM) més prednisona en CPRC com a segona línia de tractament després de la progressió a docetaxel.Este estudio retrospectivo evalúa eficacia y tolerabilidad de ciclofosfamida oral metronómica más prednisona en CPRC como segunda línea de tratamiento tras la progresión a docetaxel

Resultados a largo plazo en el tratamiento del osteosarcoma : experiencia de 20 años

Hem analitzat de manera retrospectiva una sèrie de 58 pacients diagnosticats d'un osteosarcoma no metastàsic a l'Hospital Universitari La Fe de València entre els anys 1985 i 2005. La supervivència global obtinguda als 5 i 10 anys va ser del 57 i del 50 % respectivament. Hem identificat com a factors pronòstic independents la grandària tumoral i la localització axial. Un 50% dels pacients van morir com a conseqüència d'una recidiva sistèmica malgrat haver estat tractats, la majoria, amb cirurgia amb conservació de membre i quimioteràpia tant pre com postoperatòria. El rescat quirúrgic de la recidiva proporciona supervivències prolongades d'una manera significativa.Analizamos de manera retrospectiva una serie de 58 pacientes diagnosticados de un osteosarcoma no metastásico en el Hospital Universitari La Fe de Valencia entre los años 1985 y 2005. La supervivencia global obtenida a los 5 y 10 años fue del 57 % y 50 % respectivamente. Hemos identificado como factores pronóstico independientes el tamaño tumoral y la localización axial. Un 50 % de los pacientes fallecieron como consecuencia de una recidiva sistémica a pesar de haber sido tratados, en su mayoría, con cirugía con conservación de miembro y quimioterapia tanto pre como postoperatoria. El rescate quirúrgico de la recidiva proporciona mayores supervivencias de una manera significativa

Factores predictivos de recaída sistémica y supervivencia cáncer-específica tras recaída locorregional en cáncer de mama resecado

S'ha realitzat un anàlisi retrospectiu de variables clínic-patològiques d'una sèrie de 116 malaltes diagnosticades d'una recaiguda locorregional de càncer de mama després d'una resecció quirúrgica amb mastectomía o cirurgía conservadora a l'Hospital Universitari La Fe entre els anys 1988 i 2008. La mitjana de seguiment des del diagnòstic de la recaiguda locorregional ha sigut de 60 mesos. Cinquanta-tres malaltes (45,7%) varen desenvolupar una recaiguda sistèmica amb una tasa de supervivència cáncer-específica després de la recaiguda local als 5 i 10 anys de 67 i 54% respectivament. A l'anàlisi multivariant la presència d'invasió vàsculo-linfàtica i l'afectació cutànea (cutànides) a la recaiguda varen permanèixer com a factors predictius independents de recaiguda sistèmica i supervivència càncer-específica. La presència d'aquestos factors identifica un subgrup de malaltes d'alt risc de progressió sistèmica i mort per cáncer de mama després de la recaiguda local a les que s'hauria de considerar un tractament més intensiu.Se ha realizado un análisis retrospectivo de variables clínico-patológicas en una serie de 116 pacientes diagnosticadas de una recaída locorregional de cáncer de mama tras una resección quirúrgica con mastectomía o cirugía conservadora en el Hospital Universitario La Fe entre los años 1988 y 2008. La mediana de seguimiento desde el diagnóstico de la recaída locorregional ha sido de 60 meses. Cincuenta y tres pacientes (45,7%) desarrollaron una recaída sistémica siendo la tasa de supervivencia cáncer-específica tras la recaída local a los 5 y 10 años de 67% y 54% respectivamente. En el análisis multivariante la presencia de invasión vásculo-linfática y la afectación cutánea (cutánides) en la recaída permanecieron como factores predictivos independientes de recaída sistémica y supervivencia cáncer-específica. La presencia de estos factores identifica a un subgrupo de pacientes, con alto riesgo de progresión sistémica y muerte por cáncer de mama tras la recaída local, en las que se debe considerar un tratamiento más intensivo

Vida admirable de el glorioso thaumaturgo de Roma ... sagrado fundador de la Congregacion del Oratorio, San Felipe Neri

Sign.: [calderon]8, 2[calderón]4, A-Nn8, Oo4Letra inicial adornada y friso tip. decorativoReclamosFront. calc.: "Invenit Collado Sclpt Galceran

Sorafenib for the treatment of metastatic thyroid cancer patients

Segons resultats de fases II amb inhibidors tirosina quinasa i el coneixement de les alteracions moleculars de la carcinogènesis tiroïdal, es va dissenyar un estudi retrospectiu de pacients amb càncer de tiroide metastàtic tractats amb sorafenib. S'analitzaren la taxa de respostes, toxicitat, supervivència i la correlació amb els marcadors tumorals de 34 pacients. Segons subtipus histològic, la taxa de respostes va ser 47% en medul·lars, 19% en diferenciats i 33% en anaplàsics. La mitjana de supervivència-lliure-de-progressió va ser 13.5, 10.5 i 4.4 mesos, respectivament. Es va observar correlació significativa entre la reducció dels nivells de marcador tumoral i la resposta. El perfil de toxicitat va ser favorable.Based on recent results of several phase II studies with tyrosine kinase inhibitors and the better knowledge of molecular aberrations that characterize thyroid carcinogenesis a retrospective analysis of patients with metastatic thyroid cancer treated with sorafenib was designed. 34 patients were analyzed for response rate, toxicity, survival and tumor marker correlation. Regarding histological subtype, response rates observed were 47% for medullary, 19% for differentiated and 33% for anaplastic. Median progression-free-survival was 13.5, 10.5 and 4.4 months for differentiated, medullary and anaplastic, respectively. Significant correlation was observed between tumor marker levels reduction and response. The toxicity profile was favorable

Memòria Digital de Catalunya

Localització: Barcelona, Biblioteca de Catalunya, ms. 1072/4 (f. 180-206)Núm. 873, a la coberta ms.Data obtinguda de la coberta. Data a port.: 1884Fuente de ingreso: Compra a Elisa Castells, Vda. de Joan Almirall i Forast

Changes in liver and plasma acetylcholinesterase in rats with cirrhosis induced by bile duct ligation

Classical studies of cholinesterase activity during liver dysfunction have focused on butyrylcholinesterase (BuChE), whereas acetylcholinesterase (AChE) has not received much attention. In the current study, liver and plasma AChE levels were investigated in rats with cirrhosis induced after 3 weeks of bile duct ligation (BDL). BDL rats showed a pronounced decrease in liver AChE levels (∼50%) compared with sham-operated (non-ligated, NL) controls; whereas liver BuChE appeared unaffected. A selective loss of tetrameric (G4) AChE was detected in BDL rats, an effect also observed in rats with carbon tetrachloride-induced cirrhosis. In accordance, SDS-PAGE analysis showed that the major 55-kd immunoreactive AChE band was decreased in BDL as compared with NL. A 65-kd band, attributed in part to inactive AChE, was increased as became the most abundant AChE subunit in BDL liver. The overall decrease in AChE activity in BDL liver was not accompanied by a reduction of AChE transcripts. The loss of G4 was also reflected by changes observed in AChE glycosylation pattern attributable to different liver AChE forms being differentially glycosylated. BDL affects AChE levels in both hepatocytes and Kupffer cells; however, altered AChE expression was mainly reflected in an alteration in hepatocyte AChE pattern. Plasma from BDL rats had approximately 45% lower AChE activity than controls, displaying decreased G4 levels and altered lectin-binding patterns. In conclusion, the liver is an important source of serum AChE; altered AChE levels may be a useful biomarker for liver cirrhosis.Supported by grants from la Caixa Foundation, Instituto de Salud Carlos III (Grants 03/0038, G03/155, C03/02) and Generalitat Valenciana (CTIDIB/ 2002/42, OPVI-21-2002 & GV04B-664) from Spain.Peer reviewe

Two distinct epithelial to mesenchymal transition programmes. Control invasion and inflammation in segregated tumour cell populations

Resumen del trabajo presentado al 19th Christmas Meeting del Instituto de Neurociencias (CSIC-UMH) celebrado el 21 de diciembre de 2022.Epithelial plasticity is at the core of crucial processes including embryonic cell migration, cancer progression, organ tibrosis and tissue repair. The epithelial to mesenchymal transition (EMT) triggers cell plasticity in all these contexts, highlighting its pleiotropy and intrinsic complcxity. Seminal studies have classified EMT states in cancer celllines and animal modcls. This varicty ofEMT phenotypes necds further investigation, particularly those relevant to the progression ofprevalent and dcvastating diseases such as cancer. Our objcctive is to analyse at single-cell level how different EMT states are established in tumours and if different EMT states pcrform different functions during tumour progression.Peer reviewe

C.E.R.A. en administración mensual corrige y mantiene niveles estables de hemoglobina en pacientes con enfermedad renal crónica no en diálisis: estudio observacional MICENAS II

BACKGROUND AND OBJECTIVE: C.E.R.A. (continuous erythropoietin receptor activator, pegilated-rHuEPO ß) corrects and maintains stable hemoglobin levels in once-monthly administration in chronic kidney disease (CKD) patients. The aim of this study was to evaluate the management of anemia with C.E.R.A. in CKD patients not on dialysis in the clinical setting. METHODS: Two hundred seventy two anemic CKD patients not on dialysis treated with C.E.R.A. were included in this retrospective, observational, multicentric study during 2010. Demographical characteristics, analytical parameters concerning anemia, treatment data and iron status were recorded. RESULTS: C.E.R.A. achieved a good control of anemia in both naïve patients (mean Hemoglobin 11.6g/dL) and patients converted from a previous ESA (mean Hemoglobin 11.7g/dL). Most naïve patients received C.E.R.A. once monthly during the correction phase and required a low monthly dose (median dose 75 µg/month). The same median dose was required in patients converted from a previous ESA, and it was lower than recommended in the Summary of Product Characteristics (SPC). Iron status was adequate in 75% of anemic CKD patients, but only 50% of anemic patients with iron deficiency received iron supplementation. CONCLUSIONS: C.E.R.A. corrects and maintains stable hemoglobin levels in anemic CKD patients not on dialysis, requiring conversion doses lower than those recommended by the SPC, and achieving target hemoglobin levels with once-monthly dosing frequency both in naïve and converted patients

Recent Changes in Breast Cancer Incidence in Spain, 1980–2004

BACKGROUND: Since the 1980s, Spain experienced two decades of sharply increasing breast cancer incidence. Declines in breast cancer incidence have recently been reported in many developed countries. We examined whether a similar downturn might have taken place in Spain in recent years. METHODS: Cases of invasive female breast cancer were drawn from all population-based Spanish cancer registries that had at least 10 years of uninterrupted registration over the period 1980-2004. Overall and age-specific changes in incidence rates were evaluated using change-point Poisson models, which allow for accurate detection and estimation of trend changes. All statistical tests were two-sided. RESULTS: A total of 80,453 incident cases of invasive breast cancer were identified. Overall age- and registry-adjusted incidence rates rose by 2.9% (95% confidence interval [CI] = 2.7% to 3.1%) annually during the 1980s and 1990s; there was a statistically significant change in this trend in 2001 (95% CI = 1998 to 2004; P value for the existence of a change point <.001), after which incidence declined annually by 3.0% (95% CI = 1.8% to 4.1%). This trend differed by age group: There was a steady increase in incidence for women younger than 45 years, an abrupt downturn in 2001 for women aged 45-64 years, and a gradual leveling off in 1995 for women aged 65 years or older. Separate analyses for registries that had at least 15 years of uninterrupted registration detected a statistically significant interruption of the previous upward trend in breast cancer incidence in provinces that had aggressive breast cancer screening programs and high screening participation rates, including Navarra (change point = 1991, P < .001), Granada (change point = 2002, P = .003), Bizkaia (change point = 1998, P < .001), Gipuzkoa (change point = 1998, P = .001), and Araba (change point = 1997, P = .002). CONCLUSIONS: The recent downturn in breast cancer incidence among Spanish women older than 45 years is best explained by a period effect linked to screening saturation.Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP) (AC07-005 to M.P., PM07-004 to R.P-B.) and Carlos III Institute of Health (ISCIII-CIBERESP collaborative agreement “Acción Transversal del Cancer”).S